Phase 3 Recruiting Industry
The primary objective is to determine the safety and efficacy of belzupacap sarotalocan (bel-sar) compared to sham control in patients with primary indeterminate lesions (IL) or small choroidal melanoma (CM).
Sponsor: Aura Biosciences
NCT ID: NCT06007690
Sites in Alabama: - Retina Consultants of Alabama — Birmingham, Alabama
Phase 3 Recruiting Industry
This is a Phase 3, multicenter, open-label, randomized, parallel group, treatment study to assess the efficacy and safety of lifileucel in combination with pembrolizumab compared with pembrolizumab alone in participants with untreated, unr…
Sponsor: Iovance Biotherapeutics, Inc.
NCT ID: NCT05727904
Sites in Alabama: - University of Alabama at Birmingham: The Kirklin Clinic — Birmingham, Alabama
Phase 2 Recruiting Network
This phase II trial compares the effect of encorafenib, binimetinib, and nivolumab versus ipilimumab and nivolumab in treating patients with BRAF- V600 mutant melanoma that has spread to the brain (brain metastases). Encorafenib and binime…
Sponsor: SWOG Cancer Research Network
NCT ID: NCT04511013
Sites in Alabama: - University of Alabama at Birmingham Cancer Center — Birmingham, Alabama
- Thomas Hospital — Fairhope, Alabama
- Mobile Infirmary Medical Center — Mobile, Alabama
Phase 1, Phase 2 Recruiting Network
This phase I/II trial evaluates the highest safe dose, side effects, and possible benefits of tegavivint in treating patients with solid tumors that has come back (recurrent) or does not respond to treatment (refractory). Tegavivint interf…
Sponsor: Children's Oncology Group
NCT ID: NCT04851119
Sites in Alabama: - Children's Hospital of Alabama — Birmingham, Alabama
Phase 1, Phase 2 Recruiting Industry
The goal of this clinical trial is to learn if DOC1021 + pIFN will be safe and will lead to tumor responses in patients with refractory melanoma. DOC1021 is a dendritic cell immunotherapy derived from a patient's own blood cells and loaded…
Sponsor: Diakonos Oncology Corporation
NCT ID: NCT07288112
Sites in Alabama: - The University of Alabama at Birmingham — Birmingham, Alabama
Phase 1 Recruiting Industry
The purpose of this clinical trial is to learn the safety and effects of the study medicine (PF-07799544) alone or in combination as a potential cancer treatment for adults with advanced solid tumors. The study will be conducted in two par…
Sponsor: Pfizer
NCT ID: NCT05538130
Sites in Alabama: - The Kirklin Clinic of UAB Hospital — Birmingham, Alabama
- The University of Alabama at Birmingham — Birmingham, Alabama
- University of Alabama at Birmingham - Phase I Clinical Trials Unit — Birmingham, Alabama
Recruiting Network
This study gathers health information for the Project: Every Child for younger patients with cancer. Gathering health information over time from younger patients with cancer may help doctors find better methods of treatment and on-going ca…
Sponsor: Children's Oncology Group
NCT ID: NCT02402244
Sites in Alabama: - Children's Hospital of Alabama — Birmingham, Alabama
- USA Health Strada Patient Care Center — Mobile, Alabama
NA Recruiting Academic/Other
Patients with a primary invasive melanoma are recommended to undergo excision of the primary lesion with a wide margin. There is evidence that less radical margins of excision may be just as safe. This is a randomised controlled trial of 1…
Sponsor: Melanoma and Skin Cancer Trials Limited
NCT ID: NCT03860883
Sites in Alabama: - University of South Alabama Mitchell Cancer Institute — Mobile, Alabama
Recruiting Industry
International registry for cancer patients evaluating the feasibility and clinical utility of an Artificial Intelligence-based precision oncology clinical trial matching tool, powered by a virtual tumor boards (VTB) program, and its clinic…
Sponsor: Massive Bio, Inc.
NCT ID: NCT03452774
Sites in Alabama: - Massive Bio SYNERGY-AI site — Birmingham, Alabama
- Massive Bio SYNERGY-AI site — Mobile, Alabama
Recruiting Industry
The purpose of ORACLE is to demonstrate the ability of a novel ctDNA assay developed by Guardant Health to detect recurrence in individuals treated for early-stage solid tumors. It is necessary that ctDNA test results are linked to clinica…
Sponsor: Guardant Health, Inc.
NCT ID: NCT05059444
Sites in Alabama: - University of Alabama at Birmingham — Birmingham, Alabama
NA Recruiting Academic/Other
This cluster-randomized comparative effectiveness trial compares a technology-based supportive cancer care (SCC) approach with a redesigned team-based supportive cancer care (SCC) approach.
Sponsor: Stanford University
NCT ID: NCT05297734
Sites in Alabama: - University of Alabama at Birmingham — Birmingham, Alabama
- University of South Alabama — Mobile, Alabama
Recruiting Industry
This study will evaluate the effectiveness of T-DXd in patients with HER2-positive (IHC 3+) locally advanced, unresectable, or metastatic solid tumors who have received prior systemic treatment for metastatic or advanced disease and have n…
Sponsor: AstraZeneca
NCT ID: NCT07124000
Sites in Alabama: - Research Site — Birmingham, Alabama